drugset / Trial / NCT07680257
An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors
Phase 0
Recruiting
18 enrolled
Celest Therapeutics (Shanghai) Co., Ltd.
The First Affiliated Hospital of Anhui Medical University · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
An open label, single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen receptor T cell in advanced solid tumor.
Timeline
- Start
- 2025-12-27
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SUV2208A | Cell therapy | — | Intravenous |